Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Sees Large Increase in Short Interest

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 20,045 shares, a growth of 660.7% from the April 15th total of 2,635 shares. Currently, 3.7% of the company’s stock are short sold. Based on an average daily trading volume, of 242,685 shares, the days-to-cover ratio is presently 0.1 days.

Sigyn Therapeutics Price Performance

Shares of OTCMKTS SIGY opened at $0.03 on Tuesday. The business has a 50-day moving average of $0.04 and a two-hundred day moving average of $0.91. The company has a market capitalization of $85,598.00 and a price-to-earnings ratio of -0.01. Sigyn Therapeutics has a 1 year low of $0.01 and a 1 year high of $5.00.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.